ATOS News
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdatePR NewswireSEATTLE, Nov. 10, 2026 SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc...
PR Newswire
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdatePR NewswireSEATTLE, Nov. 10, 2026 SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc...
PR Newswire
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business TodayPR NewswireSEATTLE, Oct. 19, 2026 One CVR will attach to each...
PR Newswire
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher ValuePR...
PR Newswire
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review VoucherPR NewswireSEATTLE...
PR Newswire
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of AgingPR NewswireSEATTLE...
PR Newswire
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire SEATTLE, Aug. 7, 2026 SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc...
PR Newswire
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive...
PR Newswire
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare...
PR Newswire
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire SEATTLE, June 12, 2026 $4.5 million upfront with up to an additional...
PR Newswire
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire SEATTLE, June 11, 2026 $4.5 million upfront with up to an additional $12 million of...
PR Newswire